Strategic expansion Yposkesi is expanding capacity with a second large-scale facility to be EMA and FDA compliant, signaling increased manufacturing capacity and potential for new collaborations in late-stage gene therapy programs.

AAV and LV platforms The company offers full cGMP manufacturing for lentiviral vectors and AAV platforms, including recent launches like LentiSure and AAVelocity, presenting cross-sell opportunities to partners seeking comprehensive viral vector solutions.

Genopole footprint Located on the Genopole Campus near Paris with a growing footprint, Yposkesi is well-positioned to attract European biotech partnerships seeking proximity to a robust life sciences ecosystem and research talent.

Growth-focused team With a staff size approaching 200 and ongoing leadership appointments, there is strong potential for collaborative ventures that leverage their operational scale, quality culture, and rapid deployment capabilities for late-stage programs.

Quality and compliance Recent platform launches and regulatory-aligned infrastructure indicate readiness to support regulated clinical and commercial ATMP manufacturing, making Yposkesi a viable partner for GMP-certified viral vector supply.